Stay updated with breaking news from Katherineb peters. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The novel drug BMX-001 showed improved survival in certain patients with high-grade glioma and reduced cognitive decline caused by radiation therapy. ....
/PRNewswire/ Servier will showcase new data from its vorasidenib clinical development program in a plenary townhall at the 28th Annual Meeting of the. ....
Katherine B. Peters, MD, PhD, discusses findings from the phase 3 INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 glioma harboring an IDH1 or IDH2 mutation. ....
E-Mail DURHAM, N.C. - Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they ve grown back, enabling up to 20% of patients to live well beyond predicted survival times. What causes this effect has long been the pursuit of researchers hoping to harness immunotherapies to extend more lives. New insights from a team led by Duke s Preston Robert Tisch Brain Tumor Center provide potential answers. The team found that recurring glioblastoma tumors with very few mutations are far more vulnerable to immunotherapies than similar tumors with an abundance of mutations. The finding, appearing online Jan. 13 in the journal ....